Aduro Biotech, Inc. today announced highlights from a poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer being held in National Harbor, Maryland on the preliminary safety and efficacy of its novel immunotherapy, CRS-207, being evaluated in unresectable malignant pleural mesothelioma. These data were from the second cohort of patients in an ongoing Phase 1b clinical trial of CRS-207 in combination with standard of care chemotherapy and immune-modulating doses of cyclophosphamide as a first-line treatment.
